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Abstract 
The effectiveness of cognitive-behavior treatment (CBT) in nonalcoholic fatty liver disease 
(NAFLD), largely related to overweight/obesity and considered the hepatic expression of the 
metabolic syndrome (MS), has so far been tested in very limited samples. In a tertiary referral 
center, consecutively-observed NAFLD subjects were offered a CBT program aimed at 
weight loss and increased physical activity, based on 13 group sessions; 68 cases entered the 
treatment protocol, those who refused (n=82) were given recommendations for diet and 
physical activity. Treatment goals (weight loss ≥ 7% initial b.w., normalization of liver 
enzymes and improved parameters of MS) were tested by logistic regression at 6 months (all 
cases) and at 2 years, both on intention-to-treat (ITT) and in completers (Diet, 78; CBT, 65). 
The results were adjusted for the propensity score of attending the CBT program, based on 
civil, anthropometric and clinical variables. At baseline the CBT group had a larger 
prevalence of obesity and more severe insulin resistance (HOMA assessment). At follow-up, 
CBT was associated with a higher probability of weight loss and normal liver enzymes (6-
month: odds ratio (OR), 2.56; 95% confidence interval (CI), 1.15-5.69; 2-year ITT: OR, 3.57, 
95% CI, 1.59-8.00), after adjustment for propensity and changes in body weight. A similar 
trend was observed in the outcome goals of insulin resistance and the score of MS, which 
were both reduced. In conclusion, subjects with NAFLD participating in a CBT program 
significantly improve their general and liver parameters. The beneficial effects are largely 
maintained at 2-year follow-up, in keeping with the lifestyle-related pathogenesis of disease.  
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Introduction 
Nonalcoholic fatty liver disease (NAFLD), now considered the hepatic expression of the 
metabolic syndrome (MS) (1), represents the most common cause of altered liver enzymes 
(2), namely alanine aminotransferases (ALT), which constitutes the first-level diagnostic tool 
for hepatic steatosis, together with bright liver at ultrasonography (3). The increasing 
prevalence of NAFLD in the general population has close associations with the global 
epidemics of obesity and diabetes (4), which are also linked to more severe fibrosis and 
increased risk for liver-related morbidity and mortality in subjects progressing to 
nonalcoholic steatohepatitis (NASH) (5). The high prevalence of associated metabolic 
disorders and additional features of MS explains why patients with NAFLD are also at 
significant risk for cardiovascular disease (6), which in most series dictates prognosis more 
than liver disease progression. Consequently, attempts at finding effective treatments have 
taken a similar course as other obesity-related chronic diseases and traditionally involve 
weight reduction and medical management of cardiovascular risk factors with the aim of 
removing steatosis and preventing fibrosis progression. Weight loss programs including diet 
(7), nutritional counseling (8), anti-obesity and insulin sensitizing drug therapy (both 
metformin and glitazones)(9) and bariatric surgery (10) have all been trialed. With the 
exception of surgery, promising short-term effects are followed by disappointing results in 
the long term (11) or when drug is discontinued (12).  
Despite the recognized benefits of weight reduction, maintaining weight loss in clinical 
practice is difficult. Structured programs of cognitive-behavioral treatment (CBT) have been 
advocated to improve adherence (13), but their effects have been tested only in very limited 
groups and the methodology of intervention is usually scarcely defined (13). Their usefulness 
has been validated within research settings in metabolic diseases (14-16), also outside 
research centers (17). CBT is designed to adopt a holistic approach to lifestyle intervention 
incorporating improvements to dietary intake and physical activity through multi-disciplinary 
behavior change models. The equal importance of physical activity and psychological 
strategies to maintain new behaviors is expected to have additional effects on blood lipids, 
liver fat and cardiovascular risk, compared to what is expected with dietary prescription 
alone. A one-year randomized controlled study involving only 31 patients has recently 
demonstrated a beneficial effect of CBT on histological outcomes in NAFLD (18). 
The present observational study is based on an audit of service delivery in standard practice, 
aimed at defining the effects of a structured program of CBT on obesity, cardiovascular risk 
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factors and liver enzyme levels, in a large cohort of subjects attending a referral center for 
NAFLD. Data were analyzed by procedures that provide statistical significance to the results. 
 
Materials & Methods 
A total of 176 NAFLD patients attended our tertiary referral outpatient department for 
treatment during the period January 2005 - December 2007. Twenty-six (14.7%) did not 
return for the scheduled diagnostic work-up appointments and were not considered. We 
report data on the remaining 150 cases (Table 1) who, at time of analysis (June 2010), had 
completed a 2-year follow-up and whose data had been registered at 6 months (short-term, 
n=150), 12 months (medium-term, n=145) and 2 years (long-term, n=143; CBT, 65 cases; 
Diet, 78). Since 2005, all subjects referred to the unit of Clinical Dietetics because of raised 
liver enzymes and sonographic evidence of fatty liver have had an extensive evaluation of 
their metabolic profile, including an oral glucose tolerance test in the absence of overt 
diabetes. According to a pre-defined protocol, during the first visit they receive detailed 
information about the long-term risk of advanced liver disease and meet a dietician, who 
performs a structured interview on their dietary pattern and on the past and recent history of 
body weight and physical activity. At the end of the diagnostic work-up, all subjects are 
invited to participate in a cognitive-behavioral treatment (CBT) program aimed at lifestyle 
changes (see below), following a motivational interview. The patients are informed about the 
group nature of the program, the duration of the weekly meetings and its total length, and the 
potential barriers to group sessions are explored to reduce later dropout. All subjects who 
refuse the CBT program receive a moderately restricted diet, tailored on individual 
preferences, and general guidelines for physical activity. According to our protocol, liver 
biopsy is usually postponed (by at least one year), depending on the time-course of liver 
enzymes. 
Follow-up visits are scheduled at 3 months (end of CBT) and 6 months in subjects enrolled 
into the CBT program and at 1, 3 and 6 months in patients who receive the tailored diet, to 
monitor body weight, the metabolic profile and to reinforce motivation for weight loss. All 
subjects are then seen every 6 months to promote maintenance of weight loss and to 
strengthen adherence to increased physical activity. 
Metformin was the first-line treatment in all subjects with overt diabetes (n = 43; 21 in the 
CBT group, 22 in the Diet arm), with glyclazide (6 cases), repaglinide (2 cases) or glitazones 
(only 2 cases intolerant to metformin) as second line. The glucose-lowering treatment with 
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metformin or glitazones was maintained unchanged throughout the study period, whereas the 
treatment with insulin secreting agents was reduced and eventually stopped according to 
weight loss and improved metabolic control. 
All subjects signed an informed consent to data collection and analysis. The plan of the 
present report was approved by the Senior staff committee of the Department, an Institutional 
Review Board regulating non-interventional studies.  
 
Cognitive-behavioral program 
Our CBT program is delivered during 13 weekly sessions, 120 min each, supported by a 
residential manual based on the principles of LEARN program for weight control. Group 
sessions (approx. 15-20 subjects), chaired by physicians, dieticians, psychologists, 
communication experts and physical trainers, integrate education with cognitive behavioral 
procedures and strategies. Education addresses the following main topics: a) energy balance; 
b) the alimentary pyramid, size of portions and regular eating; c) calorie counting; d) 
shopping and food labels; e) physical activity, when and how much. Cognitive behavioral 
procedures and strategies include: a) self-monitoring of food intake and body weight; b) 
stimulus control strategies; c) problem solving; d) cognitive restructuring of dysfunctional 
thoughts that obstacle weight loss; d) relapse prevention   
Upon entering the CBT program, the patients cease any prescriptive diet they might have 
followed in the past, and start with a self-managed, nutritional plan. 
Measures 
Body weight and height, waist circumference and blood pressure were measured as 
previously reported (1). Body mass index (BMI) is weight (kg) divided by height (m)2. A 7% 
decrease in body weight was selected as outcome measure considering that this value was 
also the chosen target in the Diabetes Prevention Program (14), the Look AHEAD study (19) 
and in the trial comparing CBT with standard nutritional treatment in NASH (18). 
The measurement of plasma glucose, total cholesterol, HDL-cholesterol, triglycerides and 
liver enzymes (aspartate and alanine aminotransferase - AST and ALT) were measured with 
routine assays using internal and external quality controls. Insulin resistance was calculated 
according to the homeostasis model assessment (HOMA) method (20), on the basis of 
glucose and insulin concentrations.   
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The diagnosis of type 2 diabetes and prediabetes (impaired fasting glucose (IFG)) was based 
on history and on biochemistry at the time of the first visit, according to the criteria of the 
World Heath Organization (21). The diagnosis of MS was made on the basis of three or more 
of the criteria of National Cholesterol Education Program-Adult Treatment Panel III (ATPIII) 
(22), recently harmonized with the criteria of the International Diabetes Federation (23). 
Physical fitness was tested in a population sub-sample by the calculation of oxygen 
consumption (VO2max) on a treadmill (RunRace, Technogym, Gambettola (FC), It), during 
three 5-min stages of exercise at graded heart rate (55%, 60% and 65% of maximal 
theoretical heart rate). VO2max was extrapolated by regression to maximum heart rate. 
In all cases the percent of steatosis was estimated by means of an algorithm, based on clinical 
and biochemical parameters (presence of MS and type 2 diabetes, fasting insulin, AST and 
AST/ALT ratio), recently validated against proton magnetic resonance of the liver (24). 
Sample size 
According to our previous experience, approximately 25% of cases normalize liver enzymes 
in the short term, following a prescriptive diet. To be meaningful for clinical purposes, we 
considered that CBT could double the probability of normal liver enzymes (50% of cases). 
Accordingly, at least 50 cases per group were needed, considering an  error of 0.05 and a  
error of 0.2, and a drop-out rate of 20%. An interim analysis was carried out when this 
number became available in the CBT arm at the 2-year follow-up and was repeated when all 
cases reached the 2-year follow-up.  
Statistical analysis 
Data were extracted from the general database using specific subroutines and were analyzed 
per protocol using StatView 5.0™ (SAS Institute Inc., Cary, NC.) and SPSS v11.0.4 (SPSS 
Inc., Chicago, IL). Unpaired t-test (2-tail), chi2-contingency test and Fisher’s exact test were 
used, whenever appropriate, to test differences in baseline values. Both an intention-to-treat 
(ITT) and a per-protocol analysis was carried out on the time-course of biochemical and 
clinical data by means of repeated-measures, time x treatment ANOVA. The last-
observation-carried-forward (LOCF) technique was used to complete the dataset in subjects 
missed at follow-up after 1 year. Considering that missed data were < 5%, only the ITT 
analysis is reported in text, tables and figures (no differences compared with the per-protocol 
analysis). 
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To adjust for baseline differences between groups, a propensity score analysis was used. The 
propensity score was calculated by logistic regression analysis; it defines the probability to 
adhere to the structured program, compared to subjects given the prescriptive diet, on the 
basis of at baseline. The propensity score does not only define the conditional probability to 
accept a specific treatment given clinical and biochemical individual characteristics (BMI, 
ALT, individual features of MS), but also includes variables which constitute potential 
barriers to CBT group treatment. In particular, age, sex, marital status, educational level, 
occupation, distance from the CBT center were considered (see Table 1). The last two 
variables are intimately linked to time constraints and to the economic burden of the program. 
The propensity scores were then used to adjust for baseline values in logistics regression 
analysis in 5 different models, having weight loss, ALT normalization, HOMA-IR values 
below the 75° percentile of normal (2.7%)(25) and a reduced score of MS as the dependent 
variables. Values were also corrected for changes in percent BODY WEIGHT during the 
observation period. Two upper limits of ALT were considered as dependent variables: 1) the 
standard values used in our Departments (40 U/L) and 2) an updated definition of healthy 
ranges, (<31U/L men; <19U/L women) proposed in 2002 (26). 
Further, we checked the validity of our model testing the association between treatment group 
and target ALT in a subset of matched cases. For this purpose, the whole database was 
ordered for propensity score, and each subject treated by CBT was pair-matched with a case 
treated by prescriptive diet. To achieve a perfect matching, only the 5 cases preceding or 
following the index case in the list were considered.  Using this criterion, we could match 43 
CBT-treated cases. Subsequently, the association of the CBT program with treatment 
outcomes was reassessed in this cohort by logistic regression, after adjustment for propensity 
and percent body weight, as needed.  
Data in text and in tables are given as means ± standard deviation or as median (interquartile 
range – IQR), due to non Gaussian distribution. The significance level was set at P < 0.05.  
Results 
Baseline characteristics 
Compared to subjects who limited the intervention to the prescriptive diet, the subjects 
entering the CBT program were more frequently females, with a larger proportion of 
housewives, employed and retired people; they also had a higher BMI and higher insulin 
resistance (Table 1). Among the features of MS, the CBT group had a very high prevalence 
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of waist circumference exceeding the ATP-III cut-off (90% vs. 56%; p < 0.001, Figure 1), 
without significant differences in the prevalence of other criteria or in the overall prevalence 
of MS (71% vs. 66%; p = 0.600).  
At baseline, the prediction algorithm proposed by Kotronen et al (24) identified NAFLD in 
139/150 cases at the sensitivity cut-off of 86% (> -0.640). The 11 missing cases were 7 in the 
diet group, 4 in the CBT program. The estimated percentage of liver fat was similar in the 2 
groups (diet, 10.9 ± 6.2% vs. 12.2 ± 7.3 in the CBT group; P = 0.231), and above the 
estimated cut-off value of 55.6 mg triglyceride/g liver tissue in 128 cases (68 (83%) in the 
diet group, 60 (88%) in CBT), without differences between groups (P = 0.488).  
Effects of treatment  
Only 7 cases (4 in the Diet group, 3 in the CBT group) were lost to follow-up in the period 
between 6 months and 2 years from entry into the study. In response to treatment, a 
significant percent reduction of body weight was observed in the CBT group after 6 months 
(median, -4.8%; interquartile range (IQR), 5.8), which was even larger at 2 years (median, -
5.6%; IQR, 7.0)(P vs. baseline, < 0.001 for both). The changes observed in the prescriptive 
diet group were also statistically significant, but remarkably lower, both at 6 months (median, 
-1.8%; IQR, 5.3; P < 0.001) and at 2 years (-1.4%; IQR, 6.3; P = 0.004) (Figure 2). 
Average fasting glucose levels progressively decreased during follow-up, to 100 mg/dL in the 
CBT group and to 101 mg/dL in the Diet group at 6 months, to 99 and 100 mg/dL at 12 
months and to 98 and 101 mg/dL at 2 years, respectively, without differences in the two 
groups.  By contrast, the changes in HOMA were more marked in the CBT group. At 6 
months HOMA levels in the CBT cases were no longer different from those observed in the 
Diet group and continued to decline throughout the observation period (Figure 2). 
Both AST and ALT were reduced during follow-up. The CBT group demonstrated a 
significantly greater decrease in ALT compared to diet prescription. Within 6 months the 
average ALT was under the normal threshold in the CBT group but not in the diet group 
(38.6 ± 15.5 vs. 59.6 ± 31.8 mU/mL p<0.001) and this was maintained throughout the 
following 2 years (35.5 ± 15.0 vs. 51.8 ± 26.8 p<0.001)(Figure 2). At 6 months, the 
prevalence of cases with ALT levels within the normal range was 60% in the CBT group and 
30% in the Diet group (P < 0.001, Fisher’s exact test). The difference was maintained at 2 
years (62% vs. 38%; P < 0.001).   
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All these changes were accompanied by a remarkable improvement in the other features of 
MS (namely blood glucose, HDL-cholesterol and triglycerides, mainly in the CBT group – 
not reported in details). In particular, glyclazide treatment was reduced (one case) or stopped 
(one case) in two of the 3 CBT cases with diabetes in the course of the 2-year follow-up, 
whereas it was maintained in the 3 cases treated by prescriptive diet.  
Determinants of changes 
In the first logistic regression model (Table 2), we tested the association of the treatment 
program with the achievement of significant weight loss (defined as >7% b.w.). In both the 
short (6 months) and long (2 years) term, the CBT program was more effective than diet, with 
those in the CBT group 2.53 times more likely to maintain this weight loss target at 2 years 
compared to those in the diet group. 
In the second model adjusted for propensity, ALT levels within normal values (<40mU/ml) 
were significantly associated with participation in the CBT program and this favorable effect 
was maintained after further adjustment for changes in body weight. The results of the 
sensitivity analysis using the updated lower healthy ALT cut-offs (26) did not differ 
significantly (not reported in details). The participation in the CBT program increased the 
probability to reach the targets in the short-term, but at 2 years the association with the lower 
healthy cut-offs was no longer maintained after adjustments.  
In the third model having HOMA-IR < 2.7 as outcome, after adjustment for propensity the 
subjects in the CBT group were several times more likely to achieve the target, compared to 
the diet group at 2 years. The modeling showed that this association was not solely accounted 
for by the greater decrease in body weight following CBT.  
Finally, in the fourth model having changes in the score of MS as dependent variable, 
participation in the CBT program increased the probability of reducing the score by at least 1 
point, but adjustment for weight loss cancelled out the significance.   
The exclusion of the 11 cases who were not classified as NAFLD on the basis of the 
predictive algorithm (24) did not change the results of the various models (not reported in 
details).   
 
Pair-matched analysis 
These results were confirmed by the analysis of 43 pair-matched cases having similar 
propensity levels. The average propensity score was 0.50 ± 0.19% in the CBT group and 0.52 
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± 0.19 in the Diet group (P = 0.732). At two years, CBT treatment was associated with a 
much higher probability to maintain weight loss > 7% (odds ratio (OR), 2.92; 95% 
confidence interval (CI), 1.12-7.57; P = 0.028). In addition, the subjects in the CBT group 
were much more likely to have ALT levels within the normal range (OR, 3.09; 95% CI, 1.20-
7.93; P = 0.019) as well as HOMA-IR < 2.7 (OR, 6.99; 95% CI, 1.75-27.98; P = 0.006) and a 
reduced MS score (OR, 2.95; 95% CI, 1.08-8.02; P = 0.034), after adjustment for both 
propensity score and changes in body weight.  
 
Physical fitness 
The evaluation of physical fitness was carried out in 29 patients (16 in the diet group, 13 in 
the CBT sample) at baseline and after 6 months. Their entry clinical and laboratory values 
were not statistically different from those observed in the total sample. In particular, the BMI 
was 34.0 ± 6.2 kg/m2 and 28.9 ± 5.8 in CBT and diet, respectively (P = 0.031). At baseline, 
physical fitness was moderately lower in subjects entering the CBT program (VO2max, 27.0 
± 5.7 mL/kg/min, compared with those in the diet group (31.1 ± 5.2; p = 0.052). After 6 
months, the values of the two groups were perfectly similar (32.0 ± 7.1 mL/kg/min in the 
CBT and 31.2 ± 5.5 in the Diet group), due to a significant improvement only observed in the 
CBT group (+5.0 ± 3.7 mL/kg/min; p vs. baseline, < 0.001). 
 
Discussion 
The study shows that a CBT program managed within a tertiary referral centre is associated 
with a larger weight loss and a significant improvement in insulin sensitivity and in liver 
enzymes in subjects with NAFLD, compared with a standard dietary prescription. The 
beneficial effects partly extend to the features of MS in a relatively long-term follow-up. 
CBT has been extensively investigated in metabolic diseases, namely in obesity (27), in 
subjects at risk (14, 15) or with overt diabetes in the community (28), as well as in subjects 
with mild hypertension to prevent progression to organ disease (16). In all cases, CBT was 
effective, and possibly more effective and long-lasting than drug treatment. The association 
between NAFLD and MS was the reason why we tested CBT in our patients, and the results 
were consistent with those in other associated conditions. Our study lends support to a 
seminal experience in a general population of obese subjects with liver disease (29), where 
CBT showed beneficial effects on liver enymes. 
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The strength of this study is the availability of data on consecutive subjects who agreed to 
participate to the CBT program, thus reflecting the “real world” hospital care of NAFLD 
cases. The low drop out rate of 14% (26/176) reduces the confounding effect of attrition 
which often occurs in weight loss studies. Clinical data of dropouts were not different from 
those observed in subjects who agreed to follow-up (data not shown).  
The majority of subjects were compliant to long-term follow-up, particularly subjects 
entering the CBT program, where the regular contact with therapists and clinicians may help 
maintain motivation and compliance with lifestyle changes, and facilitate weight loss and 
weight-loss maintenance (27). All cases were highly motivated to change their lifestyle when 
first seen for their elevated liver enzymes, steatosis and associated metabolic diseases. The 
participation in the CBT program was however hindered by individual barriers to group 
attendance, which were partly explored at interview (marital status, job-related time 
constraints and loss of income, living far from the center), limiting the applicability of CBT 
to the whole group of NAFLD cases. Stress, eating when bored, loss of motivation and 
thinking in ‘black and white’ have been identified as the main barriers to weight loss in CBT 
programs (30). These cognitive factors were addressed in our program, and the development 
of coping strategies might have improved weight loss outcomes. 
To cope with this difficulty, the effects of treatments were analyzed using a propensity score 
approach. The results are definitely less solid than those obtained by randomised controlled 
trials (31), but adjusting by propensity produces valuable data reflecting the “real world” of 
disease treatment and the procedure is largely accepted in chronic diseases. The propensity 
score was developed on the basis of individual characteristics, including factors related to 
barriers to group participation; comparison by propensity in the matched population provides 
a comparison similar to that obtained by random allocation, and further strengthens the 
complete series.  
Effects on liver enzymes levels were largely confirmed by the sensitivity analysis having the 
updated healthy ranges of ALT (26) as dependent variable. Although a few studies failed to 
validate liver enzymes as surrogate marker of disease severity (32), other studies showed an 
association of elevated ALT with advanced disease (33), progression to diabetes (34) and to 
MS (35), and of cardiovascular risk in the general population (36), also within “healthy” 
ranges. In conclusion, any decrease in ALT may be beneficial, and our data suggest that CBT 
is likely to promote a significant advantage over prescriptive diet in NAFLD subjects. 
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The CBT program was associated with a larger weight loss in our NAFLD cases. The 7% 
decrease in BODY WEIGHT was selected as outcome measure in keeping with several 
intervention studies of CBT in metabolic disorders (14, 19), including the very recent trial 
comparing CBT with standard nutritional treatment in NASH (18). In this last study a weight 
loss > 7% was indeed associated both with improved biochemistry and with improved liver 
histology. Interestingly, the effectiveness of weight loss on histological outcomes was partly 
independent of treatment allocation, but the weight loss target was more frequently reached in 
CBT-treated subjects. However, RCT studies in the area of behavioral modifications are 
hampered by a very high attrition rate; in spite of local advertisement, intense support and 
honorarium at completion of trial, this study recruited only 65 cases, 41 entered the study and 
only 28 completed the study (18).   
Reduced levels of alanine aminotransferases were not solely related to decreased body 
weight, since the results were partly maintained after adjustment for differences in weight 
loss. The CBT program devoted part of its education to implement physical activity in 
NAFLD patients. The program was largely derived from a CBT program for the treatment of 
obesity, coupled with a program specifically devoted to physical activity used to reinforce 
weight loss and weight loss maintenance (37). NAFLD patients are characterized by low 
levels of physical activity (38), and higher levels of exercise are associated with greater 
reduction in ALT, independent of weight change (39). Four weeks of aerobic exercise 
training was shown to be adequate to reduce hepatic triglyceride by 21% in the absence of 
body weight loss (40). In order to achieve and maintain behavior changes associated with 
greater physical activity, specific cognitive abilities must be implemented. This was part of 
the CBT program, and translated into an increase in physical fitness in the subpopulation 
where it was tested at 6-month follow-up. Improved physical fitness has been previously 
associated with decreased liver fat (41), and may account for the relative independence of 
enzyme changes from weight loss in the CBT group. Potential strategies to improve uptake of 
exercise in NAFLD have been recently reported, and should be incorporated into the standard 
of care of Liver units (42). 
In addition to reduced liver enzymes, CBT improved insulin sensitivity in the long-term. 
After 2 years, the CBT program was associated with an increased probability to achieve 
normal HOMA-R, after adjustment for propensity. The statistical modeling suggested that the 
amount of weight loss has a pivotal effect on this outcome, as well as on liver enzymes. In the 
Diabetes Prevention Program, CBT was extremely effective in reducing the progression to 
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MS in subjects at risk of diabetes (43). In our cases, with a high prevalence of obesity class 2 
or more or overt diabetes, the effects were mostly limited to triglyceride and HDL-cholesterol 
levels, or to reduced blood pressure. However, also treatment with oral hypoglycemic agents 
was reduced or stopped during follow-up, in keeping with improved insulin sensitivity.  
The study has limitations too. A major limitation is the lack of histological data. The use of 
liver biopsy for diagnostic and outcome purposes in NAFLD is a matter of discussion outside 
research projects (44), because it is costly, rarely impacts on treatment decisions and is 
potentially dangerous. The present analysis is based on the standard of care provided to our 
patients, where NAFLD is tentatively diagnosed by biochemistry and liver ultrasonography. 
However, in over 90% of cases the diagnosis was also in keeping with a recently validated 
predictive algorithm (24), without quantitative differences in liver fat between groups. 
According to our protocol, liver biopsy is postponed and only proposed to patients who fail to 
improve with standard treatment. Recently, new tests of fibrosis have been validated (45), but 
were not available when the study was planned. Future studies should expand the limited 
experience of CBT against histological outcomes reported so far (18), or test the effectiveness 
of lifestyle modifications against validated biochemical tests of fibrosis. 
Second, the intensity and the number of contacts between patients and therapists were much 
higher in the CBT program than in the control treatment. In addition, the CBT program was 
delivered as group sessions, while participants in the control group had only individual 
contacts with the therapists. Therefore, the more favorable results obtained by the CBT 
program on weight loss, liver enzymes, and other metabolic indices might also be the 
consequences of the more intense and frequent contacts with the therapists or of the group 
support. Future studies should clarify this important issue. 
It is also possible that patients accepting the CBT program form a rather selected group with 
potentially higher intrinsic motivation, related to higher BMI and multiple comorbidities (46), 
as well as the higher prevalence of females, who generally have more time available for 
intensive group care and different motivation for weight loss (47). These factors are expected 
to translate into better weight loss outcomes. In the future, a quantitative assessment of 
motivation should be introduced as a possible baseline indicator of treatment allocation and 
adherence.  
In conclusion, data derived from our observational analysis support CBT as a useful approach 
to NAFLD treatment, to replace the standard dietary approach. Any effort should be done to 
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provide motivated patients effective treatment, as well as remove barriers that may reduce 
their compliance. Both patients and physicians should consider lifestyle changes as an 
essential component of treatment to be systematically offered to NAFLD cases, not merely as 
an optional adjunct to drug treatment.  
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Legend for figures 
Figure 1  
Prevalence of features of the ATPIII-defined metabolic syndrome in the NAFLD population, 
divided according to the type of treatment program (open bars, Prescriptive Diet; closed bars, 
Cognitive-Behavioral Treatment).  
 
Note that the only difference is in the prevalence of cases with waist circumference ≥102 cm 
in males and ≥88 cm in females (p < 0.001).  
 
Figure 2 
Effects of different treatment programs on percent weight loss (upper panel), HOMA values 
(middle panel) and alanine transaminases (lower panel).  
 
Closed circles identify CBT treatment; open circles are subjects treated by the prescriptive 
diet. Data are presented as means ± 95% confidence intervals. The time courses of the three 
variables are significantly different between groups (repeated measures, time x treatment 
ANOVA) 
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Table 1 
Clinical characteristics of subjects treated by the cognitive-behavioral program and by 
prescriptive diet (mean ± SD or percent of cases *(95% confidence interval)). 
 
 CBT group 
(n = 68) 
Prescriptive diet 
(n = 82) 
P value 
Female gender (%) 64 (49 – 74)* 35 (25 – 49)* < 0.001 
Marital status (Single/Married/Widowed 
or Divorced)(%) 
22/69/9 41/50/9 0.035 
Education (Primary/Secondary/ 
Vocational/Degree)(%) 
12/38/34/18 10/33/40/17 0.869 
Profession (Student/Housewife/ 
Employee/Self-employed/Retired)(%) 
4/11/49/13/23 6/0/61/11/22 0.053 
Place of residence (within town/ 
metropolitan area/regional area) (%) 
62/29/9 63/26/11 0.825 
Age (years) 53 ± 12 50 ± 14 0.159 
Body mass index (kg/m2) 36.2 ± 4.7 30.5 ± 5.1 < 0.001 
Waist circumference (cm) 110 ± 11 106 ± 12 < 0.001 
NGT/IFG-IGT/Diabetes° (%) 48/21/31 50/23/27 0.825 
Fasting glucose 105 ± 24 107 ± 29 0.802 
Fasting insulin (µU/mL) 21.0 ± 8.7 16.8 ± 8.6 0.002 
HOMA (%) 5.53 ± 2.68 4.45 ± 2.52 0.012 
HDL-cholesterol (mg/dL) 48.0 ± 10.3 46.4 ± 12.8 0.377 
Triglycerides (mg/dL) 178 ± 77 205 ± 108 0.100 
Systolic pressure (mmHg) 134 ± 13 132 ± 13 0.206 
Diastolic pressure (mmHg) 85 ± 8 85 ± 9 0.933 
Aspartate aminotransferases (U/L) 38 ± 17 43 ± 22 0.167 
Alanine aminostransferases (U/L) 64 ± 33 73 ± 42 0.165 
Prevalence of criteria of the metabolic 
syndrome (0/1/2/3/4/5)(%) 2/7/21/26/35/9 4/15/16/30/28/7 0.578 
°NGT, normal glucose tolerance; IFG, Impaired fasting glucose; IGT, impaired glucose 
tolerance 
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Table 2 
Logistic regression models on the association of treatment program with weight changes (> 
7% initial body weight), normal ALT levels, normal HOMA-IR and reduced score of the 
metabolic syndrome at 6 months and at 2 years in NAFLD subjects. 
 
 6-month results 
OR (95% CI) 
2-year results 
OR (95% CI)* 
Dependent variable: weight loss > 7% initial b.w.   
Comparator (Prescriptive diet) 1 1 
CBT program (unadjusted) 4.15 (1.76 - 9.75) 3.18 (1.44 - 7.00) 
Adjusted for propensity 2.22 (0.86 - 5.75) 2.53 (1.04 - 6.14) 
   
Dependent variable: normal ALT (<40 mU/mL)   
Comparator (Prescriptive diet) 1 1 
CBT program (unadjusted) 3.46 (1.76 - 6.81) 4.09 (2.06 - 8.12) 
Adjusted for propensity 3.26 (1.51 - 7.05) 4.13 (1.88 - 9.08) 
Adjusted for propensity and % change in b.w.  2.58 (1.18 - 5.72) 3.57 (1.59 - 8.00) 
   
Dependent variable: normal HOMA-IR (<2.7%)   
Comparator (Prescriptive diet) 1 1 
CBT program (unadjusted) 2.53 (0.95 - 6.76) 4.79 (1.89 - 12.13) 
Adjusted for propensity 2.41 (0.79 - 7.35) 7.15 (2.39 - 21.36) 
Adjusted for propensity and % change in b.w. 2.32 (0.78 - 7.24) 5.21 (1.74 - 15.59) 
   
Dependent variable: decreased score of the 
Metabolic Syndrome  
  
Comparator (Prescriptive diet) 1 1 
CBT program (unadjusted) 0.95 (0.49 - 1.84) 2.16 (1.11 - 4.19) 
Adjusted for propensity 1.51 (0.33 - 6.96) 2.69 (1.23 - 5.86) 
Adjusted for propensity and % change in body 
weight 
1.05 (0.51 - 2.26) 1.97 (0.87 - 4.45) 
 
*Two-year data were analyzed by intention-to-treat using the last-observation-carried-
forward technique (cases missed at follow-up: Diet 3, CBT, 4). 
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Figure 1 
 
 
 
 
Prevalence of features of the ATPIII-defined metabolic syndrome in the NAFLD population, divided 
according to the type of treatment program (open bars, Prescriptive Diet; closed bars, Cognitive- 
Behavioral Treatment). 
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Figure 2 
 
 
 
Effects of different treatment programs on percent weight loss (upper panel), HOMA values (middle 
panel) and alanine transaminases (lower panel). 
Closed circles identify CBT treatment; open circles are subjects treated by the prescriptive diet. 
Data are presented as means ± 95% confidence intervals. The time courses of the three variables 
are significantly different between groups (repeated measures, time x treatment ANOVA) 
 
